RT Journal Article
SR Electronic
T1 Dystonia-Parkinsonism Gene Variants in Individuals with Parkinsonism and Brain Scans without Evidence for Dopaminergic Deficit (SWEDD)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.21.22271781
DO 10.1101/2022.03.21.22271781
A1 Nudelman, Kelly N. H.
A1 Xiong, Yajing
A1 Cook, Lola
A1 Schulze, Jeanine
A1 Abreu, Marco
A1 Marek, Kenneth
A1 Singleton, Andrew
A1 Foroud, Tatiana
A1 Chahine, Lana M.
A1 The Parkinson’s Progression Markers Initiative
YR 2022
UL http://medrxiv.org/content/early/2022/03/21/2022.03.21.22271781.abstract
AB Objective To investigate the genetic etiology of dystonia-parkinsonism among individuals with parkinsonism who have dopamine transporter (DAT) SPECT scans without evidence of dopaminergic deficits (SWEDD).Methods Data for this case-control study were from the Parkinson’s Progression Markers Initiative (PPMI) cohort, a multisite observational study. The sample analyzed included participants with whole genome sequencing (WGS) who were diagnosed as Parkinson’s disease (PD, n=421), SWEDD (n=64) or healthy controls (HC, n=196). WGS data were analyzed to identify rare pathogenic variants in 30 dystonia-parkinsonism genes. Rare variants were prioritized for those present in individuals with SWEDD, but not in HC, reported pathogenicity in the literature and genetic databases, and with data from programs analyzing variant conservation and effect on protein function. For each SWEDD case with predicted or reported pathogenic variant(s), demographic, clinical, and imaging data were reviewed.Results Eight of the 64 SWEDD participants (12.5%) had a pathogenic variant in one or more dystonia-parkinsonism genes, including PRKRA, SGCE, GLB1, ADCY5, SLC6A3, and GCDH. Notably, one case had a heterozygous variant in SGCE, p.R263H, which is predicted pathogenic but currently classified as a variant of uncertain significance due to insufficient evidence.Conclusions Pathogenic variants in parkinsonism-dystonia genes occurred in more than 10% of SWEDD cases in the PPMI cohort, supporting the importance of considering dystonia disorders in the differential diagnosis of PD, particularly in the case of participants with normal DAT SPECT scans. Analysis of genetic variants in parkinsonism-dystonia genes in SWEDD cases can provide information which will improve clinical diagnosis and management.What is already known on this topic Individuals with parkinsonism with scans without evidence of dopamine deficiency (SWEDD) constitute up to 16% of subjects with early parkinsonism referred for inclusion in multicenter observational studies and randomized clinical trials; however, the majority of these individuals do not have Parkinson’s disease. Dystonic disorders are high on the list of differential diagnoses for individuals with parkinsonism and SWEDD, and an increasing number of studies support genetic etiologies for dystonic disorders. What proportion of individuals with parkinsonism and SWEDD referred for research studies might carry pathogenic variants in dystonia-parkinsonism related genes is not known.What this study adds This study identified predicted or reported pathogenic variants in dystonia-parkinsonism related genes in more than 10% of SWEDD cases in the PPMI cohort, supporting the utility of evaluating dystonia-parkinsonism related genetic etiology in SWEDD cases.How this study might affect research, practice, or policy This study supports the importance of genetic analyses in SWEDD cases which could improve clinical diagnosis and patient management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are supported by funding from the Michael J. Fox Foundation for Parkinson&#39s Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used in the preparation of this article were obtained from the Parkinson&#39s Progression Markers Initiative (PPMI) database (www.ppmi-info.org/access-data-specimens/download-data). For up-to-date information on the study, visit https://www.ppmi-info.org/.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the preparation of this article were obtained from the Parkinson&#39s Progression Markers Initiative (PPMI) database (https://www.ppmi-info.org/access-data-specimens/download-data). For up-to-date information on the study, visit https://www.ppmi-info.org/.